Overview

Open-Label Extension Study of ASTORIA

Status:
Not yet recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.
Phase:
Phase 2
Details
Lead Sponsor:
Contera Pharma A/S